Welcome to the July 2025 edition of Electric Vehicle [EV] company news. The past month saw another strong result for EV sales ...

Detailed price information for Cellectis S.A. ADR (CLLS-Q) from The Globe and Mail including charting and trades.

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...